Clinical Trial

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, PK and immunogenicity of SV001 in patients with idiopathic pulmonary fibrosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-12.
Status change: Not Yet Recruiting → Recruiting 2026-02-08
Trial Details
NCT Number NCT07121413
Lead Sponsor Shanghai Synvida Biotechnology Co.,Ltd.
Conditions Idiopathic Pulmonary Fibrosis(IPF)
Enrollment 48 participants
Start Date 2025-11-04
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-11